Neopterin to monitor clinical pathologies involving interferon-γ production

Pteridines

Volumn 15, Issue 3, 2004, Pages 75-90

  Schroecksnadel, Katharina ^a   Murr, Christian ^a   Winkler, Christiana ^a,b   Wirleitner, Barbara ^a,b   Fuith, Lothar C ^c   Fuchs, Dietmar ^a,b,d  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^d Institute of Biochemistry   (Austria)

Author keywords

Cellular immune response; Immunobiology; In vitro testing; Laboratory diagnosis; Neopterin

Indexed keywords

ALPHA TOCOPHEROL; ANTIBODY; ANTIOXIDANT; ANTIRETROVIRUS AGENT; ATORVASTATIN; BACTERIUM LIPOPOLYSACCHARIDE; CD4 ANTIGEN; CONCANAVALIN A; GAMMA INTERFERON; GUANOSINE TRIPHOSPHATE; LYMPHOKINE; NEOPTERIN; PHENYLALANINE; PHYTOHEMAGGLUTININ; PTERIDINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; TRYPTOPHAN; VIRUS RNA;

AGING; ARTICLE; BILIARY EXCRETION; BLOOD LEVEL; BLOOD TRANSFUSION; CELLULAR IMMUNITY; CEREBROSPINAL FLUID; CYTOKINE PRODUCTION; DIFFERENTIAL DIAGNOSIS; GRAFT REJECTION; HELPER CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOBIOLOGY; INFECTION; LABORATORY DIAGNOSIS; MONITORING; NONHUMAN; ORGAN TRANSPLANTATION; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; TISSUE INJURY; URINE LEVEL; VIRUS REPLICATION;

BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS;

EID: 4644335290     PISSN: 09334807     EISSN: 21954720     Source Type: Journal    
DOI: 10.1515/pteridines.2004.15.3.75     Document Type: Article

References (163)

1. Kraut H, Pabst W, Rembold H, Wildemann L. On the behavior of biopterin in the mammalian body. I. Balance and growth experiments on rats. Hoppe Seyler's Z Physiol Chem 1963; 332: 101-108.
2. Pabst W, Rembold H. On the behavior of biopterins in the mammalian organism. II. Effect of vitamin deficiency and of an antagonist on biopterin differentiation and on the growth of the rat. Hoppe Seyler's Z Physiol Chem 1966; 344: 107-112.
3. Rembold H, Gyure WL. Biochemistry of the pteridines. Angew Chem Int Ed Engl. 1972; 11: 1061-1072.
4. Pfleiderer W. New developments in pteridine chemistry. Angew Chemie 1963; 75: 993-1040.
5. Niederwieser A, Curtius HC, Bettoni O, Bieri J, Schircks B, Viscontini M, Schaub J. Atypical phenylketonuria caused by 7, 8-dihydrobiopterin synthetase deficiency. Lancet. 1979; 1: 131-133.
6. Wachter H, Hausen A, Graßmayr K. Erhöhte Ausscheidung von Neopterin im Harn von Patienten mit malignen Tumoren und Viruserkrankungen. Biol Chem Hoppe-Seyler 1979; 360: 1957-1960.
7. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today 1988; 9: 150-155.
8. Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER. Neopterin as a marker for activation of cellular immunity: Immunologic basis and clinical application. Adv Clin Chem 1989; 27: 81-141.
9. Wachter H, Fuchs D, Hausen A, Reibnegger G, Weiss G, Werner ER, Werner-Felmayer G. Neopterin - Biochemistry Methods Clinical Application. Berlin-New York: Walter de Gruyter 1992.
10. Widner B, Murr C, Wirleitner B, Mayr C, Spöttl N, Baier-Bitterlich G, Fuchs D. The importance of neopterin as a laboratory diagnostic marker of immune activation. Pteridines 1999; 10: 101-111.
11. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab 2002; 3: 175-187.
12. Werner-Felmayer G, Golderer G, Werner ER. Tetrahydrobiopterin biosynthesis, utilization and pharmacological effects. Curr Drug Metab 2002; 3: 159-173.
13. Werner ER, Werner-Felmayer G, Fuchs D, Hausen A, Reibnegger G, Yim JJ, Pfleiderer W, Wachter H. Tetrahydrobiopterin biosynthetic activities in human macrophages fibroblasts THP-1 and T 24 cells GPT-cyclohydrolase I is stimulated by interferon-γ 6-pyruvoyl tetrahydropterin synthase and sepiapterin reductase are constitutively present. J Biol Chem 1990; 265: 3189-3192.
14. Fuchs D, Milstien S, Krämer G, Reibnegger G, Werner ER, Dierich MP, Wachter H. Urinary neopterin concentrations versus total neopterins for clinical utility. Clin Chem 1989; 35: 2305-2307.
15. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, Reibnegger G, Swetly P, Troppmair J, Wachter H. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon gamma. J Exp Med 1984; 160: 310-316.
16. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H. Tumor necrosis factor-α and lipopolysaccharide enhance interferon-induced tryptophan degradation and pteridine synthesis in human cells. Biol Chem Hoppe-Seyler 1989; 370: 1063-1069.
17. Wirleitner B, Reider D, Ebner S, Bock G, Widner B, Jaeger M, Schennach H, Romani N, Fuchs D. Monocyte-derived dendritic cells release neopterin. J Leukocyte Biol 2002; 72: 1148-1153.
18. Andert SE, Griesmacher A, Zuckermann A, Müller MM. Neopterin release from human endothelial cells triggered by interferon-gamma. Clin Exp Immunol 1992; 88: 555-558.
19. Moutabarrik A, Takahara S, Nakanishi I, Kokado Y, Takano Y, Kameoka H, Ishibashi M, Zaid D. Interferon-γ stimulates neopterin release from cultured kidney epithelial cells. Scand J Immunol 1994; 39: 27-30.
20. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Schmidt K, Weiss G, Wachter H. Pteridine biosynthesis in human endothelial cells. Impact on nitric oxide-mediated formation of cyclic GMP. J Biol Chem 1993; 268: 1842-1846.
21. Abita JP, Cost H, Milstien S, Kaufman S, Saimot G. Urinary neopterin and biopterin levels in patients with AIDS and AIDS-related complex. Lancet 1995; 2: 51-52.
22. Fuchs D, Blair JA, Wachter H. Does increased neopterin during cell-mediated immune response stem from activated macrophages? Pteridines 1996; 7: 45-46.
23. Brown RR, Lee CM, Kohler PC, Hank JA, Storer BE, Sondel PM. Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin-2. Cancer Res 1989; 49: 4941-4944.
24. Marth C, Weiss G, Koza A, Reibnegger G, Daxenbichler G, Zeimet AG, Fuchs D, Wachter H, Dapunt O. Increased production of immune activation marker neopterin by colony-stimulating factors in gynecological cancer patients. Int J Cancer 1994; 58: 20-23.
25. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996; 9: 532-562.
26. Denz H, Fuchs D, Hausen A, Huber H, Nachbaur D, Reibnegger G, Thaler J, Werner ER, Wachter H. Value of urinary neopterin in the differential diagnosis of bacterial and viral infections. Klin Wochenschr 1990; 68: 218-222.
27. Weiss G, Murr C, Zoller H, Haun M, Widner B, Ludescher C, Fuchs D. Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells. Clin Exp Immunol 1999; 116: 435-440.
28. Ledochowski M, Murr C, Widner B, Fuchs D. Inverse relationship between neopterin and immunoglobulin E. Clin Immunol 2001; 98: 104-108.
29. Murr C, Hainz U, Asch E, Berger P, Jenewein B, Saurwein-Teissl M, Grubeck-Loebenstein B, Fuchs D. Association of increased neopterin production with decreased humoral immunity in the elderly. Exp Gerontol 2003; 38: 583-587.
30. Romagnani S. Th1 and Th2 in human disease. Clin Immunol Immunopathol 1996; 80: 225-235.
31. Weiss G, Schwaighofer H, Herold M, Nachbaur D, Wachter H, Niederwieser D, Werner ER. Nitric oxide formation as predictive parameter for acute graft-versus-host disease after human allogeneic bone marrow transplantation. Transplantation 1995; 60: 1239-1244.
32. Nathan CF. Peroxide and pteridine: A hypothesis on the regulation of macrophage antimicrobial activity by interferon-g. In: Gresser I, Vilcek J, eds. Interferon 7. London: Academic Press 1986; 125-143.
33. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313.
34. Fuchs D, Baier-Bitterlich G, Wede I, Wachter H. Reactive oxygen and apoptosis. In: Scandalios J, ed. Oxidative Stress and the Molecular Biology of Antioxidant Defenses. Cold Spring Harbor-New York: Cold Spring Harbor Laboratory Press 1997; 139-167.
35. Murr C, Fuith L-C, Widner B, Wirleitner B, Baier-Bitterlich G, Fuchs D. Increased neopterin concentrations in patients with cancer: indicator of oxidative stress? Anticancer Res 1999; 19(3A): 1721-1728.
36. Weiss G, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Semenitz E, Dierich MP, Wachter H. Neopterin modulates toxicity mediated by reactive oxygen and chlorine species. FEBS Lett 1993; 321: 89-92.
37. Murr C, Fuchs D, Gössler W, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Esterbauer H, Wachter H. Enhancement of hydrogen peroxide-induced luminol-dependent chemiluminescence by neopterin depends on the presence of iron chelator complexes. FEBS Lett 1994; 338: 223-226.
38. Heales SJR, Blair JA, Meinschad C, Ziegler I. Inhibition of monocyte luminol-dependent chemiluminescence by tetrahydrobiopterin and the free radical oxidation of tetrahydrobiopterin dihydrobiopterin and dihydropterin. Cell Biochem Funct 1988; 6: 191-195.
39. Baier-Bitterlich G, Fuchs D, Murr C, Reibnegger G, Werner-Felmayer G, Sgonc R, Böck G, Dierich MP, Wachter H. Effect of neopterin and 7,8-dihydroneopterin on tumor necrosis factor-a induced programmed cell death. FEBS Lett 1995; 364: 234-238.
40. Murr C, Baier-Bitterlich G, Fuchs D, Werner ER, Esterbauer H, Pfleiderer W, Wachter H. Effects of neopterin-derivatives on H2O2-induced luminol chemiluminescence: mechanistic aspects. Free Radic Biol Med 1996; 21: 449-456.
41. Wede I, Semenitz E, Wachter H, Fuchs D. Neopterin and 7,8-dihydroneopterin modulate microbicidal effects of reactive oxygen and chlorine species on Escherichia coli. Pteridines 1996; 7: 64-65.
42. Öttl K, Wirleitner B, Baier-Bitterlich G, Grammer T, Fuchs D, Reibnegger G. Formation of oxygen radicals in solutions of 7,8-dihydroneopterin. Biochem Biophys Res Commun 1999; 264: 262-267.
43. Schneemann M, Schoedon G, Hofer S, Blau N, Guerrero L, Schaffner A. Nitric oxide synthase is not a constituent of the antimicrobial armature of human mononuclear phagocytes. J Infect Dis 1993; 167: 1358-1363.
44. Kolb JP, Paul-Eugene N, Damais C, Yamaoka K, Drapier JC, Dugas B. Interleukin-4 stimulates cGMP production by IFN-gamma-activated human monocytes. Involvement of the nitric oxide synthase pathway. J Biol Chem 1994; 269: 9811-9816.
45. Fuchs D, Murr C, Reibnegger G, Weiss G, Werner ER, Werner-Felmayer G, Wachter H. Nitric oxide synthase and antimicrobial armature of human macrophages. J Infect Dis 1994; 169: 224-225.
46. Baier-Bitterlich G, Fuchs D, Zangerle R, Baeuerle PA, Werner ER, Fresser F, Überall F, Baier G, Wachter H. Transactivation of the HIV-1 promoter by 7,8-dihydroneopterin in vitro. AIDS Res Hum Retroviruses 1997; 13: 173-178.
47. Hoffmann G, Schobersberger W, Frede S, Pelzer L, Fandrey J, Wachter H, Fuchs D, Grote J. Neopterin activates transcription factor nuclear factor-kB in vascular smooth muscle cells. FEBS Lett 1996; 391: 181-184.
48. Razumovitch JA, Semenkova GN, Fuchs D, Cherenkevich SN. Influence of neopterin on the generation of reactive oxygen species in human neutrophils. FEBS Lett 2003; 549: 83-86.
49. Solichová D, Melichar B, Svobodová I, Bláha V, Zadák Z. Fluorescence analysis of antioxidant vitamins and neopterin in nonagenarians. Biomed Chromatogr 1999; 13: 117-118.
50. Sattler W, Leblhuber F, Walli J, Widner B, Fuchs D. Cerebrospinal fluid levels of a-tocopherol and neopterin in patients with dementia. Pteridines 1999; 10: 220-224.
51. Hagberg L, Dotevall L, Norkrans G, Larsson M, Wachter H, Fuchs D. Cerebrospinal fluid neopterin concentrations in central nervous system infection. J Infect Dis 1993; 168: 1285-1288.
52. Fuchs D, Werner ER, Wachter H. Soluble products of immune activation: neopterin. In: Rose NR, Conway de Macario E, Fahey JL, Friedman H, Penn GM, eds. Manual of clinical Laboratory Immunology. Washington DC: American Society for Microbiology 1992; 251-255.
53. Reibnegger G, Auhuber I, Fuchs D, Hausen A, Judmaier G, Prior C, Werner ER, Wachter H. Urinary neopterin levels in acute viral hepatitis. Hepatology 1988; 8: 771-774.
54. Reibnegger G, Fuchs D, Grubauer G, Hausen A, Wachter H. Neopterin excretion during incubation period clinical manifestation and reconvalescence of viral infection. In: Pfleiderer W, Wachter H, Curtius HC, eds. Biochemical and Clinical Aspects of Pteridines. Vol 3. Berlin-New York: Walter de Gruyter 1984; 433-437.
55. Tilg H, Margreiter R, Scriba M, Marth C, Niederwieser D, Aulitzky W, Spielberger M, Wachter H, Huber C. Clinical presentation of CMV infection in solid organ tranplant recipients and its impact on graft rejection and neopterin excretion. Clin Transplantation 1987; 1: 37-43.
56. Griffin DE, Ward BJ, Jauregui E, Johnson RT, Vaisberg A. Immune activation during measles: interferon gamma and neopterin in plasma and cerebrospinal fluid in complicated and uncomplicated disease. J Infect Dis 1990; 161: 449-453.
57. Zaknun D, Weiss G, Glatzl J, Wachter H, Fuchs D. Neopterin levels during acute rubella in children. Clin Infect Dis 1993; 17: 521-522.
58. Schennach H, Meyersbach P, Schönitzer D, Fuchs D. Additional neopterin screening to improve safety of blood donations. Pteridines 2000; 11: 76-80.
59. Baize S, Leroy EM, Georges AJ, Georges-Courbot MC, Capron M, Bedjabaga I, Lansoud-Soukate J, Mavoungou E. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 2002; 128: 163-168.
60. Zangerle R, Schönitzer D, Fuchs D, Most J, Dierich MP, Wachter H. Reducing HIV transmission by seronegative blood. Lancet 1992; 339: 130-131.
61. Fuchs D, Banekovich M, Hausen A, Hutterer J, Reibnegger G, Werner ER, Gschnait FD, Dierich MP, Wachter H. Neopterin estimation compared with the ratio of T-cell subpopulations in persons infected with human immunodeficiency virus-1. Clin Chem 1988; 34: 2415-2417.
62. Fuchs D, Wachter H. Neopterin - ein Marker für den zellulären Immunstatus - Bedeutung bei AIDS, ARC und AIDS-Risikogruppen, in: AIDS (Gschnait F, Wolff K, eds.), Springer-Verlag, Wien, New York, 1985, pp 97-127.
63. Melmed RN, Taylor JMG, Detels R, Bozorgmehri M, Fahey JL. Serum neopterin changes in HIV-infected subjects: indicator of significant pathology CD4 T cell changes and the development of AIDS. J Aquir Immune Defic Syndr 1989; 2: 70-76.
64. Fuchs D, Spira TJ, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Wachter H. Neopterin as a predictive marker for disease progression in human immunodeficiency virus type 1 infection. Clin Chem 1989; 35: 1746-1749.
65. Fahey JL, Taylor JMG, Detels R, Hofman B, Melmed R, Nishanian P, Giorgi JV. The prognostic value of cellular and serological markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990; 322: 166-172.
66. Zangerle R, Fuchs D, Reibnegger G, Fritsch P, Wachter H. Markers of disease progression in intravenous drug users infected with HIV-1. AIDS 1991; 5: 985-991.
67. Krämer A, Biggar RJ, Hampl H, Friedman RM, Fuchs D, Wachter H, Goedert JJ. Immunologic markers of progression to acquired immunodeficiency syndrome are time-dependent and illness-specific. Am J Epidermiol 1992; 136: 71-80.
68. Mellors JW, Kingsley LA, Rinaldo CR, Todd JA, Hoo BS, Kokka RP, Gupta P. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573-579.
69. Zangerle R, Steinhuber S, Sarcletti M, Dierich MP, Wachter H, Fuchs D, Möst J. Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1 infected individuals. Int Arch Allergy Immunol 1998; 116: 228-239.
70. Gisslen M, Norkrans G, Svennerholm B, Hagberg L. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis 1997; 175: 434-437.
71. Hutterer J, Armbruster C, Wallner G, Fuchs D, Vetter N, Wachter H. Early changes of neopterin concentrations during treatment of human immunodeficiency virus infection with zidovudine. J Infect Dis 1992; 165: 783-784.
72. Niederwieser A, Joller P, Seger R, Blau N, Prader A, Bettex JD, Lüthy R, Hirschel B, Schaedelin J, Vetter U. Neopterin in AIDS, other immunodeficiencies and bacterial and viral infections. Klin Wochenschr 1986; 64: 333-337.
73. Strohmaier W, Redl H, Schlag G, Inthorn D. Deythro-neopterin plasma levels in intensive care patients with and without septic complications. Crit Care Med 1987; 15: 757-760.
74. Brown AE, Dance DAB, Chaowagul W, Webster HK, White NJ. Activation of cellular immune response in melioidosis patients assessed by urinary neopterin. Trans Roy Soc Trop Med Hyg 1990; 84: 583-584.
75. Diez-Ruiz A, Al-Amrani M, Weiss G, Gutierrez-Gea F, Wachter H, Fuchs D. Increased interferon-gamma and neopterin concentrations in patients with acute brucellosis. J Infect Dis 1993; 167: 504-505.
76. Murr C, Baier-Bitterlich G, Fuchs D, Gerlach D, Werner-Felmayer G, Dierich MP, Wachter H. Streptococcal erythrogenic toxins induce the formation of neopterin in human peripheral blood mononuclear cells but not in the human myelomonocytoma cell line THP-1. Immunobiol 1996; 195: 314-322.
77. Murr C, Gerlach D, Widner B, Dierich MP, Fuchs D. Neopterin production and tryptophan degradation in humans infected by Streptococcus pyogenes. Med Microbiol Immunol 2001; 189: 161-163.
78. Fuchs D, Hausen A, Kofler M, Kosanowski H, Reibnegger G, Wachter H. Neopterin as an index of immune response in patients with tuberculosis. Lung 1984; 162: 337-346.
79. Horak E, Gassner I, Sölder B, Wachter H, Fuchs D. Neopterin levels and pulmonary tuberculosis in infants. Lung 1998; 176: 337-344.
80. Hosp M, Elliott AM, Raynes JG, Mwinga AG, Luo N, Zangerle R, Pobee JOM, Wachter H, Dierich MP, McAdam KPWJ, Fuchs D. Neopterin, beta 2-microglobulin and the acute phase proteins in HIV-1-seropositive and -seronegative Zambian patients with tuberculosis. Lung 1997; 175: 265-275.
81. Schmutzhard E, Fuchs D, Hausen A, Reibnegger G, Wachter H. Is neopterin - a marker of cell mediated immune response-helpful in classifying leprosy? East Afr Med J 1986; 63: 577-580.
82. Reibnegger G, Boonpucknavig V, Fuchs D, Hausen A, Schmutzhard E, Wachter H. Urinary neopterin is elevated in patients with malaria. Trans Roy Soc Trop Med Hyg 1984; 78: 545-546.
83. Kern P, Hemmer CJ, Van Damme J, Gruss HJ, Dietrich M. Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria. Am J Med 1989; 87: 139-143.
84. Brown AE, Webster HK, Teja-Isavadharm P, Keeratithakul D. Macrophage activation in falciparum malaria as measured by neopterin and interferon-γ. Clin Exp Immunol 1990; 82: 97-101.
85. Reibnegger G, Fuchs D, Hausen A, Schmutzhard E, Werner ER, Wachter H. The dependence of cell-mediated immune activation in malaria on age and endemicity. Trans Roy Soc Trop Med Hyg 1987; 81: 729-733.
86. Dotevall L, Fuchs D, Reibnegger G, Wachter H, Hagberg L . Cerebrospinal fluid and serum neopterin levels in patients with Lyme neuroborreliosis. Infection 1990; 18: 210-214.
87. Gasse T, Murr C, Mayersbach P, Schmutzhard E, Wachter H, Fuchs D. Neopterin production and tryptophan degradation in acute Lyme neuroborreliosis versus late Lyme encephalopathy. Eur J Clin Chem Clin Biochem 1994; 32: 685-689.
88. Reibnegger G, Fuchs D, Fuith LC, Hausen A, Werner ER, Werner-Felmayer G, Wachter H. Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detect Prev 1991; 15: 483-490.
89. Bayram M, Bayram O, Boyunaga H, Ozer G. A research on the level of urine neopterin to see if it may provide a vital clue for a provisional diagnosis of breast cancer in menopausal women. Maturitas 2004; 48: 432-437.
90. Mura P, Piriou A, Tallineau C, Reiss D. La néopterine urinaire: Intérét dans l'exploration de certaines néoplasies. Ann Biol Clin (Paris) 1986; 44: 505-510.
91. Denz H, Grünewald K, Thaler J, Huber H, Fuch D, Hausen A, Reibnegger G, Werner ER, Wachter H. Urinary neopterin as a prognostic marker in haematological neoplasias. Pteridines 1989; 1: 167-170.
92. Reibnegger G, Krainer M, Herold M, Ludwig H, Wachter H, Huber H. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res 1991; 51: 6250-6253.
93. Reibnegger G, Bichler A, Dapunt O, Fuchs D, Fuith LC, Hausen A, Hetzel H, Lutz H, Werner ER, Wachter H. Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix. Cancer Res 1986; 46: 950-955.
94. Reibnegger G, Hetzel H, Fuchs D, Fuith LC, Hausen A, Wachter H. Clinical significance of neopterin for prognosis and follow-up in ovarian cancer. Cancer Res 1987; 47: 4977-4981.
95. Weiss G, Kronberger P, Conrad F, Bodner E, Wachter H, Reibnegger G. Neopterin and prognosis in patients with adenocarcinoma of the colon. Cancer Res 1993; 53: 260-265.
96. Kronberger P, Weiss G, Tschmelitsch J, Fuchs D, Salzer GM, Wachter H, Reibnegger G. Predictive value of urinary neopterin in patients with lung cancer. Eur J Clin Chem Clin Biochem 1995; 33: 831-837.
97. Prommegger R, Widner B, Murr C, Unger A, Fuchs D, Salzer GM. Neopterin: a prognostic variable in operations for lung cancer. Ann Thorac Surg 2000; 70: 1861-1864.
98. Lewenhaupt A, Ekman P, Eneroth P, Eriksson A, Nilsson B, Nordström L. Serum levels of neopterin as related to the prognosis of human prostatic carcinoma. Eur Urol 1986; 12: 422-425.
99. Kawasaki H, Watanabe H, Yamada S, Watanabe K, Suyama A. Prognostic significance of urinary neopterin levels in patients with hepatocellular carcinoma. Tohoku J Exp Med 1988; 155: 311-318.
100. Murr C, Berchtold J, Norer B, Waldhart E, Wachter H, Fuchs D. Neopterin as a prognostic parameter in patients with squamous cell carcinomas of the oral cavity. Int J Cancer 1998; 79: 476-480.
101. Murr C, Bergant A, Widschwendter M, Heim K, Schröcksnadel H, Fuchs D. Neopterin is an independent prognostic variable in females with breast cancer. Clin Chem 1999; 45: 1998-2004.
102. Denz H, Fuchs D, Huber H, Nachbaur D, Reibnegger G, Thaler J, Werner ER, Wachter H. Correlation between neopterin interferon-gamma and hemoglobin in patients with haematological neoplasias. Eur J Haematol 1990; 44: 186-189.
103. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. Soluble tumor necrosis factor and neopterin as parameters of cell mediated immune activation. Eur J Haematol 1995; 54: 1-8.
104. Denz H, Orth B, Weiss G, Gallati H, Hermann R, Huber P, Wachter H, Fuchs D. Serum soluble tumor necrosis factor receptor 55 is increased in patients with haematological neoplasias and is associated with immune activation and weight loss. Eur J Cancer 1993; 29A: 2232-2235.
105. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001; 85: 473-483.
106. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
107. Reibnegger G, Egg D, Fuchs D, Günther R, Hausen A, Werner ER, Wachter H. Urinary neopterin reflects clinical activity in patients with rheumatoid arthritis. Arthritis Rheumat 1986; 29: 1063-1070.
108. Märker-Alzer G, Diemer O, Strümper R, Rohe M. Neopterin production in inflammed knee joints: high levels in synovial fluids. Rheumatol Int 1986; 6: 151-154.
109. Samsonov MY, Tilz GP, Egorova O, Reibnegger G, Balabanova RM, Nassonov EL, Nassonova VA, Wachter H, Fuchs D. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus 1995; 4: 29-32.
110. Nassonov EL, Samsonov MY, Tilz GP, Beketova TV, Semenkova EN, Baranov A, Wachter H, Fuchs D. Serum concentrations of neopterin soluble interleukin 2 receptor and soluble tumor necrosis factor receptor in Wegener's granulomatosis. J Rheumatol 1997; 24: 666-670.
111. Samsonov MY, Nassonov EL, Tilz GP, Geht BM, Demel U, Gurkina GT, Shtutman VZ, Guseva AG, Wachter H, Fuchs D. Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis. Brit J Rheumatol 1997; 36: 56-660.
112. Prior C, Bollbach R, Fuchs D, Hausen A, Judmaier G, Niederwieser D, Reibnegger G, Rotthauwe HW, Werner ER, Wachter H. Urinary neopterin a marker of clinical activity in patients with Crohn's disease. Clin Chim Acta 1986; 155: 11-21.
113. Reibnegger G, Bollbach R, Fuchs D, Hausen A, Judmaier G, Prior C, Rotthauwe HW, Werner ER, Wachter H. A simple index relating clinical activity in Crohn's disease with T cell activation: hematocrit, frequency of liquid stools and urinary neopterin as parameters. Immunobiology 1986; 173: 1-11.
114. Niederwieser D, Fuchs D, Hausen A, Judmaier G, Reibnegger G, Wachter H, Huber C. Neopterin as a new biochemical marker in the clinical assessment of ulcerative colitis. Immunobiology 1985; 170: 320-326.
115. Samsonov M, Fuchs D, Reibnegger G, Belenkov JN, Nassonov EL, Wachter H. Patterns of serological markers for cellular immune activation in patients with dilated cardiomyopathy and chronic myocarditis. Clin Chem 1992; 38: 678-680.
116. Samsonov M, Tilz GP, Pisklakov VP, Reibnegger G, Nassonov EL, Nassonova VA, Wachter H, Fuchs D. Serum-soluble receptors for tumor necrosis factor-alpha and interleukin-2 and neopterin in acute rheumatic fever. Clin Immunol Immunopathol 1995; 74: 31-34.
117. Tatzber F, Rabl H, Koriska K, Erhart U, Puhl H, Waeg G, Krebs A, Esterbauer H. Elevated serum neopterin levels in atherosclerosis. Atherosclerosis 1991; 89: 203-208.
118. Erren M, Reinecke H, Junker R, Fobker M, Schulte H, Schurek JO, Kropf J, Kerber S, Breithardt G, Assmann G, Cullen P. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 1999; 19: 2355-2363.
119. Weiss G, Willeit J, Kiechl S, Fuchs D, Jarosch E, Oberhollenzer F, Reibnegger G, Tilz GP, Gerstenbrand F, Wachter H. Increased concentrations of neopterin in carotid atherosclerosis. Atherosclerosis 1994; 106: 263-271.
120. Melichar B, Gregor J, Solichova D, Lukes J, Tichy M, Pidrman V. Increased urinary neopterin in acute myocardial infarction. Clin Chem 1994; 40: 338-339.
121. Gupta S, Fredericks S, Schwartzman RA, Holt DW, Kaski JC. Serum neopterin in acute coronary syndromes. Lancet 1997; 349: 1252-1253.
122. Frick B, Rudzite V, Schroecksnadel K, Kalnins U, Erglis A, Trusinskis K, Fuchs D. Homocysteine, B vitamins and immune activation in coronary heart disease. Pteridines 2003; 14: 82-87.
123. Schumacher M, Halwachs G, Tatzber F, Fruhwald FM, Zweiker R, Watzinger N, Eber B, Wilders-Truschnig M, Esterbauer H, Klein W. Increased neopterin in patients with chronic and acute coronary syndromes. J Am Coll Cardiol 1997; 30: 703-707.
124. Garcia-Moll X, Coccolo F, Cole D, Kaski JC. Serum neopterin and complex stenosis morphology in patients with unstable angina. J Am Coll Cardiol 2000; 35: 956-962.
125. Ridker PM, Hennekens CH, Buring JE, Rifai N. Creactive protein and other markers of inflammation in prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
126. Avanzas P, Arroyo-Espliguero R, Cosin-Sales J, Quiles J, Zouridakis E, Kaski JC. Prognostic value of neopterin levels in treated patients with hypertension and chest pain but without obstructive coronary artery disease. Am J Cardiol 2004; 93: 627-629.
127. Fuchs D, Jaeger M, Widner B, Wirleitner B, Artner-Dworzak E, Leblhuber F. Is hyperhomocysteinemia due to oxidative depletion of folate rather than insufficient dietary intake. Clin Chem Lab Med 1991; 39: 691-694.
128. Fredrikson S, Link H, Eneroth P. CSF neopterin as marker of disease activity in multiple sclerosis. Acta Neurol Scand 1987; 75: 352-355.
129. Giovannoni G, Lai M, Kidd D, Thorpe JW, Miller DH, Thompson AJ, Keir G, Feldmann M, Thompson EJ. Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. Brain 1997; 120: 1-13.
130. Westarp ME, Fuchs D, Bartmann P, Hoff-Jörgensen R, Clausen J, Wachter H, Kornhuber HH. Amyotrophic lateral sclerosis - an enigmatic disease with B-cellular and anti-retroviral immune responses. Eur J Med 1993; 2: 327-332.
131. Leblhuber F, Walli J, Demel U, Tilz GP, Widner B, Fuchs D. Increased serum neopterin concentrations in patients with Alzheimer's disease. Clin Chem Lab Med 1999; 37: 429-431.
132. Leblhuber F, Walli J, Jellinger K, Tilz GP, Widner B, Laccone F, Fuchs D. Activated immune system in patients with Huntington's disease. Clin Chem Lab Med 1998; 36: 747-750.
133. Frick B, Neurauter G, Diez-Ruiz A, Schroecksnadel K, Wirleitner B, Leblhuber F, Fuchs D. Neopterin and oxidation products in the blood of patients with various forms of dementia. Pteridines 2003; 14: 88-93.
134. Widner B, Leblhuber F, Fuchs D. Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. J Neural Transm 2002; 109: 181-189.
135. Leblhuber F, Walli J, Artner-Dworzak E, Vrecko K, Widner B, Reibnegger R, Fuchs D. Hyperhomocysteinemia in dementia. J Neural Transm 2000; 107: 1469-1474.
136. Wirleitner B, Neurauter G, Schröcksnadel K, Frick B, Fuchs D. Interferon-γ-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 2003; 10: 1581-1591.
137. Schennach H, Murr C, Larcher C, Streif W, Pastner E, Zaknun D, Schönitzer D, Fuchs D. Neopterin concentrations in cord blood: a single-cohort study of paired samples from 541 pregnant women and their newborns. Clin Chem 2002; 48: 2059-2061.
138. Winkler C, Wirleitner B, Werner ER, Fuchs D. Urinary neopterin concentrations in healthy individuals with household contact. Pteridines 2003; 14: 35-38.
139. Frick B, Schroecksnadel K, Neurauter G, Leblhuber F, Fuchs D. Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin Biochem 2004; 37: 684-687.
140. Reibnegger G, Huber LA, Jürgens G, Schönitzer D, Werner ER, Wachter H, Wick G, Traill KN. Approach to define "normal ageing" in man immune function serum lipids lipoproteins and neopterin levels. Mech Ageing Dev 1988; 46: 67-82.
141. Diamondstone LS, Tollerud DJ, Fuchs D, Wachter H, Brown LM, Maloney E, Kurman CC, Nelson DL, Blattner WA. Factors influencing serum neopterin and ß2-microglobulin levels in healthy diverse population. J Clin Immunol 1994; 14: 368-374.
142. Ledochowski M, Murr C, Widner B, Fuchs D. Association between insulin, resistance body mass and neopterin concentrations. Clin Chim Acta 1999; 282: 115-123.
143. Ledochowski M, Murr C, Jäger M, Fuchs D. Dehydroepiandrosterone ageing and immune activation. Exp Gerontol 2001; 36: 1739-1747.
144. Reibnegger G, Aichberger C, Fuchs D, Hausen A, Spielberger M, Werner ER, Margreiter R, Wachter H. Posttransplant neopterin excretion in renal allograft recipients - a reliable diagnostic aid for acute rejection and a predictive marker of long-term graft survival. Tranplantation 1991; 52: 58-63.
145. Muller T, Keuchel M, Schindler S, Steinmetz A, Feiber H, Lange H. Differential, diagnosis of transplant function disorders in therapy with monoclonal antibodies OKT3. Helv Chir Acta 1991; 58: 271-275.
146. Grebe SO, Mueller TF. Immune monitoring in organ transplantation using neopterin. Curr Drug Metab. 2002; 3: 189-202.
147. Hausen A, Aichberger C, Königsrainer A, Weiss G, Margreiter R, Wachter H. Biliary and urinary neopterin concentrations in monitoring liver-allograft recipients. Clin Chem 1993; 39: 45-47.
148. Königsrainer A, Reibnegger G, Ofner D, Klima G, Tauscher T, Margreiter R. Pancreatic juice neopterin excretion: reliable marker for detection of pancreatic allograft rejection. Transplant Proc 1990; 22: 671-672.
149. Niederwieser D, Huber C, Gratwohl A, Bannert P, Fuchs D, Hausen A, Reibnegger G, Speck B, Wachter H. Neopterin as a new biochemical marker in the clinical monitoring of bone marrow transplant recipients. Transplantation 1984; 38: 497-500.
150. Reissigl H, Rosmanith P, Schönitzer D. HIV antigen study. Beitr Infusionsther 1989; 24: 14-17.
151. Hönlinger M, Fuchs D, Hausen A, Reibnegger G, Schönitzer D, Werner ER, Reissigl H, Dierich MP, Wachter H. Serum neopterin determination for the additional safeguarding of blood transfusions. Our experiences with 76587 blood donors. Dtsch Med Wochenschr 1989; 114: 172-176.
152. Schennach H, Hessenberger G, Mayersbach P, Schönitzer D, Fuchs D. Acute cytomegalovirus infections in blood donors are indicated by increased serum neopterin concentrations. Med Microbiol Immunol 2002; 191: 115-118.
153. Schennach H, Lanthaler AJ, Mayersbach P, Ulmer H, Müll K, Schönitzer D, Fuchs D, Larcher C. Human parvovirus B19 detection in asymptomatic blood donors: association with increased neopterin concentration. J Infect Dis 2002; 168: 1494-1497.
154. Schennach H, Schoenitzer D, Fuchs D. Association between chronic hepatitis C virus infection and increased neopterin concentrations in blood donations. Clin Chem 1998; 44: 2225-2226.
155. Altindag ZZ, Werner-Felmayer G, Sahin G, Wachter H, Fuchs D. Colchicine derivatives inhibit neopterin production in human peripheral blood mononuclear cells (PBMC). Clin Exp Immunol 1997; 107: 574-577.
156. Gruber A, Murr C, Wirleitner B, Werner-Felmayer G, Fuchs D. Histamine suppresses neopterin production in the human myelomonoctoma cell line THP-1. Immunol Lett 2000; 72: 133-136.
157. Zvetkova E, Wirleitner B, Tram NT, Schennach H, Fuchs D. Aqueous extracts of Crinum latifolium (L.) and Camellia sinensis show immunomodulatory properties in human peripheral blood mononuclear cells. Intern Immunopharmacol 2001; 1: 2143-2150.
158. Winkler C, Wirleitner B, Schroecksnadel K, Schennach H, Mur E, Fuchs D. In vitro effects of two extracts and two pure alkaloid preparations of Uncaria tomentosa on peripheral blood mononuclear cells. Planta Med 2004; 70: 205-210.
159. Neurauter G, Wirleitner B, Schroecksnadel K, Schennach H, Ueberall F, Fuchs D. PADMA 28 modulates interferon-γ-induced tryptophan degradation and neopterin production in human PBMC in vitro. Intern Immunopharmacol 2004; 4: 833-839.
160. Neurauter G, Wirleitner B, Schroecksnadel K, Schennach H, Fuchs D. Wine and grape juice modulate interferon-γ-induced neopterin production and tryptophan degradation in human PBMC. Pteridines 2004; 15: 1-9.
161. Neurauter G, Wirleitner B, Laich A, Schennach H, Weiss G, Fuchs D. Atorvastatin suppresses interferon-γ-induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines. Clin Exp Immunol 2003; 131: 264-267.
162. Walter RB, Fuchs D, Weiss G, Walter TR, Reinhard WH. HMG-CoA reductase inhibitors are associated with decreased serum neopterin levels in stable coronary artery disease. Clin Chem Lab Med 2003; 41: 1314-1319.
163. Werner-Felmayer G, Baier-Bitterlich G, Fuchs D, Hausen A, Murr C, Reibnegger G, Werner ER, Wachter H. Detection of bacterial pyrogens on the basis of their effects on gamma interferon-mediated formation of neopterin or nitrite in cultured monocyte cell lines. Clin Diagn Lab Immun 1995; 2: 307-313.